🇺🇸 FDA
Patent

US 10422807

Indirect homogeneous mobility shift assays for the detection of biologics in patient samples

granted A61PA61P1/04

Quick answer

US patent 10422807 (Indirect homogeneous mobility shift assays for the detection of biologics in patient samples) held by PRECISION IBD, INC. expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PRECISION IBD, INC.
Grant date
Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P1/04